Jing Xi, MD
Hematology & Oncology · Centennial, CONPI 1275983926
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Gilead at 51.3% of the total.
Across 191 payments — averaging $328.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$32K
- AstraZeneca$19K
- Stemline Therapeutics Inc.$5K
- Lilly USA, LLC$2K
- Daiichi Sankyo Inc.$431
- Genmab U.S., Inc.$396
- plus $3K from 28 others
Across 11 payments — averaging $61,902 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$504K
- Genentech, Inc.$177K
What the payments were for
- Consulting fees$22,03535%
- Speaking & faculty fees$31,77051%
- Travel & lodging$2,8525%
- Food & beverage$5,3028%
- Education$7641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 64 | $32,171 |
| AstraZeneca(2 entities) | 30 | $19,124 |
| Stemline Therapeutics Inc. | 11 | $5,022 |
| Lilly USA, LLC | 2 | $2,212 |
| Daiichi Sankyo Inc. | 11 | $431 |
| Genmab U.S., Inc. | 9 | $396 |
| Tersera Therapeutics LLC | 4 | $376 |
| GSK | 4 | $297 |
| Leica Microsystems Inc. | 1 | $280 |
| Merck | 7 | $271 |
| Novartis | 8 | $215 |
| Exelixis Inc. | 4 | $196 |
| Amgen | 2 | $188 |
| Myriad Genetic Laboratories, Inc. | 5 | $187 |
| Beigene USA, Inc. | 2 | $175 |
| Incyte Corporation | 2 | $150 |
| Tempus AI, Inc | 2 | $145 |
| Immunogen, Inc. | 1 | $135 |
| AbbVie | 2 | $111 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $100 |
| Astellas Pharma US Inc | 1 | $100 |
| Genentech USA, Inc. | 1 | $76 |
| Johnson & Johnson | 2 | $67 |
| Eisai Inc. | 2 | $50 |
| Otsuka America Pharmaceutical, Inc. | 3 | $39 |
| Bristol Myers Squibb | 1 | $34 |
| CTI Biopharma Corp. | 1 | $28 |
| Rigel Pharmaceuticals, Inc. | 1 | $27 |
| Pfizer | 2 | $25 |
| Pharmacosmos Therapeutics Inc. | 1 | $21 |
| Taiho Oncology, Inc. | 1 | $21 |
| Menarini Silicon Biosystems, Inc. | 1 | $19 |
| Caris MPI, Inc. | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$62,723 in reported general payments places this provider in the 80th percentile of 169 hematology & oncology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 28 | $440,479 |
| EliquisApixaban | 28 | $23,218 |
| Tamoxifen Citrate | 163 | $4,179 |
| Anastrozole | 246 | $2,782 |
| Dexamethasone | 82 | $1,153 |
| Letrozole | 25 | $588 |
| Prochlorperazine Maleate | 42 | $456 |
| Ondansetron Hcl | 37 | $315 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 23 | $311 |
| Duloxetine Hcl | 13 | $197 |
| Folic Acid | 52 | $194 |
| Gabapentin | 24 | $177 |
| Olanzapine | 18 | $128 |
| Mirtazapine | 13 | $82 |
| Potassium Chloride | 33 | $31 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $25 | $463,69756 claims |
| Lilly USA, LLCOlanzapine | $2,212 | $12818 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 169 hematology & oncology providers in Colorado.
Other hematology & oncology in Centennial
- Amy SchmidtDenver$2.8M
- Yousuf GaffarDenver$963K
- John BurkeAurora$321K
- Manojkumar BupathiLittleton$312K
- Steven SchusterFort Collins$298K
- Douglas ReznickAurora$294K
- Daniel PollyeaAurora$274K
- Robert RifkinDenver$270K
- Christopher BentonEnglewood$249K
- Mabel MardonesDenver$149K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.